MedTrace Logo

Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD

NCT02430896 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2019-07-05

No results posted yet for this study

Summary

The objective of this study is to identification of neuropsychological, genetic and neuroimaging markers and treatment response predictors of attention-deficit/hyperactivity disorder (ADHD). Participants who take the standardized pharmacotherapy (methylphenidate or atomoxetine) for ADHD will be observed for 52 weeks. They will do several neuropsychological, neuroimaging and genetic tests at visit 1\~6.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

Methylphenidate (MPH)

Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.

DRUG

Atomoxetine

Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Hyo-Won Kim, Professor · Asan Medical Center

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2020-06-30
Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02430896 on ClinicalTrials.gov